Disc Medicine stock price target raised to $115 by Truist on drug outlook
Truist Securities raised its price target for Disc Medicine (NASDAQ:IRON) to $115 from $83, maintaining a Buy rating. The stock surged 39% in the past week to $78.90. The firm cited confidence in the regulatory and commercial outlook for bitopertin following positive APOLLO trial results. Disc Medicine expects to resubmit its application by the end of 2026, with a potential FDA decision in mid-2027. Other analysts also raised price targets following the trial data.
How this was made
The 30-second read
Why it matters
Analyst upgrades collectively raise the stock's valuation outlook, but actual price movement depends on FDA approval timing.
Market read
The article reflects a consensus upgrade after trial data, offering modest trading insight for IRON.
What to watch
Potential competition from other photosensitivity treatments and the need for reimbursement approvals.
Background
Disc Medicine (NASDAQ:IRON) announced positive Phase 3 trial results for bitopertin, prompting several analysts to raise price targets.
Ticker impact
Truist raised Disc Medicine's price target to $115 from $83 and maintained a Buy rating after the Phase 3 APOLLO trial data.
likely upward pressure as the market prices in higher target levels
Multiple brokerages increased price targets following the same trial results, indicating consensus optimism.
Market effects
Positive sentiment may lift other biotech stocks with late‑stage trial pipelines.
US biotech sector could see modest gains in pre‑market trading.
Limited to investors tracking US‑listed biotech developments.
Counterpoint
If the FDA resubmission faces delays, the upgraded targets could be premature.
Key entities
- companyDisc Medicine
Biotech firm developing bitopertin for photosensitivity disorders.
- analystTruist Securities
Raised price target to $115 and kept a Buy rating.